Previous 10 | Next 10 |
home / stock / cphrf / cphrf news
Cipher Pharmaceuticals Inc. (CPHRF) Q4 2019 Earnings Conference Call March 26, 2020, 08:30 AM ET Company Participants Craig Mull - Interim CEO Nadine Jutlah - Interim CFO Conference Call Participants Andre Uddin - Mackie Research Capital Doug Loe - Echelon Wealth Partners ...
Cipher Pharmaceuticals ( OTC:CPHRF ): Q4 GAAP EPS of $0.10 beats by $0.06 . More news on: Cipher Pharmaceuticals Inc., Earnings news and commentary, , Read more ...
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Canada NewsWire OAKVILLE, ON, March 25, 2020 Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter OAKVILLE, ON , March 25, 2020 /CNW/ ...
Notice of Cipher Pharmaceuticals Q4 2019 Conference Call Canada NewsWire OAKVILLE, ON, Feb. 20, 2020 OAKVILLE, ON , Feb. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 2020 financial results confere...
Cipher Pharmaceuticals Provides Update on Absorica Brand Extension Program with Sun Pharmaceutical Canada NewsWire OAKVILLE, ON, Feb. 6, 2020 OAKVILLE, ON , Feb. 6, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") is pleased to announce ...
Cipher Pharmaceuticals ( OTC:CPHRF ) reports that Bausch Health Companies (NYSE: BHC ) has notified it that it intends to terminate its license agreement for constipation med Trulance (plecanatide) due to an undisclosed breach of certain provisions of the contract. More news on: Cipher P...
Cipher Pharmaceuticals ( OTC:CPHRF ) has received a Notice of Termination from Bausch Health (NYSE: BHC ) in connection with the License, Development and Commercialization Agreement of Trulance® (plecanatide). More news on: Cipher Pharmaceuticals Inc., Bausch Health Companies Inc., ...
Cipher Pharmaceuticals Receives Notice of Termination from Bausch Canada NewsWire OAKVILLE, ON, Jan. 20, 2020 OAKVILLE, ON , Jan. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Term...
Cipher Pharmaceuticals Inc. (CPHRF) Q3 2019 Earnings Conference Call November 07, 2019 08:30 AM ET Company Participants Craig Mull - Interim Chief Executive Officer Nadine Jutlah - Interim Chief Financial Officer Conference Call Participants Prasath Pandurangan - Bloom Burton...
Cipher Pharmaceuticals ( OTC:CPHRF ): Q3 GAAP EPS of -$0.08 misses by $0.12 . More news on: Cipher Pharmaceuticals Inc., Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Companhia Siderurgica Paulista Nova Cosipa Company Name:
CPHRF Stock Symbol:
OTCMKTS Market:
Companhia Siderurgica Paulista Nova Cosipa Website:
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders Canada NewsWire MISSISSAUGA, ON , June 14, 2024 /CNW/ - Cipher Pharmaceuticals Inc . (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the "Company ") today announced that i...
Cipher Pharmaceuticals Reports First Quarter 2024 Results Canada NewsWire (All figures are presented in U.S. Dollars) Adjusted EBITDA in Q1 2024 was $3.6 million , an increase of 12.5% over Q1 2023 Epuris sales volumes grew 7.2% in the quarter over Q1 2023, c...
Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call Canada NewsWire MISSISSAUGA, ON , May 3, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release ...